Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates.
Siriwattananon K, Manopwisedjaroen S, Shanmugaraj B, Rattanapisit K, Phumiamorn S, Sapsutthipas S, Trisiriwanich S, Prompetchara E, Ketloy C, Buranapraditkun S, Wijagkanalan W, Tharakhet K, Kaewpang P, Leetanasaksakul K, Kemthong T, Suttisan N, Malaivijitnond S, Ruxrungtham K, Thitithanyanont A, Phoolcharoen W. Siriwattananon K, et al. Among authors: wijagkanalan w. Front Plant Sci. 2021 May 13;12:682953. doi: 10.3389/fpls.2021.682953. eCollection 2021. Front Plant Sci. 2021. PMID: 34054909 Free PMC article.
DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.
Prompetchara E, Ketloy C, Tharakhet K, Kaewpang P, Buranapraditkun S, Techawiwattanaboon T, Sathean-Anan-Kun S, Pitakpolrat P, Watcharaplueksadee S, Phumiamorn S, Wijagkanalan W, Patarakul K, Palaga T, Ruxrungtham K. Prompetchara E, et al. Among authors: wijagkanalan w. PLoS One. 2021 Mar 22;16(3):e0248007. doi: 10.1371/journal.pone.0248007. eCollection 2021. PLoS One. 2021. PMID: 33750975 Free PMC article.
Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C, Chanthavanich P, Limkittikul K, Siegrist CA, Wijagkanalan W, Chinwangso P, Petre J, Hong Thai P, Chauhan M, Viviani S. Sirivichayakul C, et al. Among authors: wijagkanalan w. Hum Vaccin Immunother. 2017 Jan 2;13(1):136-143. doi: 10.1080/21645515.2016.1234555. Epub 2016 Sep 29. Hum Vaccin Immunother. 2017. PMID: 27686283 Free PMC article. Clinical Trial.
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Blanchard Rohner G, Chatzis O, Chinwangso P, Rohr M, Grillet S, Salomon C, Lemaître B, Boonrak P, Lawpoolsri S, Clutterbuck E, Poredi IK, Wijagkanalan W, Spiegel J, Pham HT, Viviani S, Siegrist CA. Blanchard Rohner G, et al. Among authors: wijagkanalan w. Clin Infect Dis. 2019 Mar 19;68(7):1213-1222. doi: 10.1093/cid/ciy594. Clin Infect Dis. 2019. PMID: 30759183 Clinical Trial.
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani S. Pitisuttithum P, et al. Among authors: wijagkanalan w. Lancet Infect Dis. 2018 Nov;18(11):1260-1268. doi: 10.1016/S1473-3099(18)30375-X. Epub 2018 Sep 25. Lancet Infect Dis. 2018. PMID: 30266329 Clinical Trial.
Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial.
Chatzis O, Blanchard-Rohner G, Mondoulet L, Pelletier B, De Gea-Hominal A, Roux M, Huttner A, Hervé PL, Rohr M, Matthey A, Gutknecht G, Lemaître B, Hayem C, Pham HT, Wijagkanalan W, Lambert PH, Benhamou PH, Siegrist CA. Chatzis O, et al. Among authors: wijagkanalan w. Clin Microbiol Infect. 2021 Jun;27(6):878-885. doi: 10.1016/j.cmi.2020.08.033. Epub 2020 Sep 5. Clin Microbiol Infect. 2021. PMID: 32896653 Free article. Clinical Trial.
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines.
Pitisuttithum P, Dhitavat J, Sirivichayakul C, Pitisuthitham A, Sabmee Y, Chinwangso P, Kerdsomboon C, Fortuna L, Spiegel J, Chauhan M, Poredi IK, van den Biggelaar AHJ, Wijagkanalan W, Viviani S, Mansouri S, Pham HT. Pitisuttithum P, et al. Among authors: wijagkanalan w. EClinicalMedicine. 2021 Jun 23;37:100976. doi: 10.1016/j.eclinm.2021.100976. eCollection 2021 Jul. EClinicalMedicine. 2021. PMID: 34386749 Free PMC article.
Epidermal micro-perforation potentiates the efficacy of epicutaneous vaccination.
Hervé PL, Dhelft V, Plaquet C, Rousseaux A, Bouzereau A, Gaulme L, Tilleul S, Ligouis M, Donne N, Lambert PH, Hong-Thai P, Wijagkanalan W, Sampson HA, Mondoulet L. Hervé PL, et al. Among authors: wijagkanalan w. J Control Release. 2019 Mar 28;298:12-26. doi: 10.1016/j.jconrel.2019.02.004. Epub 2019 Feb 6. J Control Release. 2019. PMID: 30738084
Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.
Fortuna L, Chaithongwongwatthana S, Soonthornworasiri N, Spiegel J, Wijagkanalan W, Mansouri S, van den Biggelaar AHJ, Pham HT. Fortuna L, et al. Among authors: wijagkanalan w. Vaccine. 2020 Dec 3;38(51):8194-8199. doi: 10.1016/j.vaccine.2020.10.070. Epub 2020 Nov 8. Vaccine. 2020. PMID: 33176935 Free article.
22 results